ERYtech Pharma Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ERYtech Pharma's estimated annual revenue is currently $4.1M per year.(i)
  • ERYtech Pharma's estimated revenue per employee is $14,130
  • ERYtech Pharma's current valuation is $71.8M. (January 2022)

Employee Data

  • ERYtech Pharma has 293 Employees.(i)
  • ERYtech Pharma grew their employee count by 1% last year.

ERYtech Pharma's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP, Legal Affairs & General CounselReveal Email/Phone
3
Director Pharmaceutical Operations and Qualified PersonReveal Email/Phone
4
Chief Financial Officer & Chief Operating OfficerReveal Email/Phone
5
Director Research and Development OperationsReveal Email/Phone
6
HUMAN RESOURCES DIRECTORReveal Email/Phone
7
Manufacturing ManagerReveal Email/Phone
8
Safety ManagerReveal Email/Phone
9
Clinical operations CRA( Senior Level)Reveal Email/Phone
10
Materials Management AssociateReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is ERYtech Pharma?

Founded in 2004, ERYtech Pharma is a biotechnology company specialized in the encapsulation of therapeutic molecules or enzymes into red blood cells. The company targets the development of products indicated in the treatment of serious types of cancer, such as solid or haematological tumours, for which existing treatments are particularly constraining. ERYtech Pharma significantly improves the therapeutic index of the encapsulated molecules or enzymes and thus patients' life conditions. Since its creation, ERYtech Pharma has received support from several national institutions.

keywords:N/A

N/A

Total Funding

293

Number of Employees

$4.1M

Revenue (est)

1%

Employee Growth %

$71.8M

Valuation

N/A

Accelerator

ERYtech Pharma News

2022-04-20 - Zacks: Analysts Anticipate ERYTECH Pharma S.A. (NASDAQ ...

Zero analysts have provided estimates for ERYTECH Pharma's earnings. The firm is scheduled to report its next quarterly earnings results on...

2022-04-06 - ERYTECH Announces Publication of Positive Results from ...

Cambridge, MA (U.S.) and Lyon (France), April 06, 2022 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical...

2022-03-30 - ERYTECH to Present Novel Vesiculation Approach at the 24th ...

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and...

2021-11-15 - ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting

ERYTECH Announces Upcoming Poster Presentation at the 2021 American Society of Hematology Annual Meeting Cambridge, MA (U.S.) and Lyon (France), November 15, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulat ...

2021-11-10 - ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal

ERYTECH Announces Publication of a Paper on Red-Blood Cell Characterization in High Impact Peer Reviewed Journal The Paper "Multiparametric characterization of red blood cell physiology after hypotonic dialysis based drug encapsulation process" is available in the October 2021 (Volume 11, Issue ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
N/A29644%N/A
#2
$59.2M299N/AN/A
#3
$235M300-5%$340.9M
#4
$79M30570%$81M
#5
$104.8M30526%N/A